Search or Ask Iris
Ctrl+K
Welcome to Multibagg AI
Log in to access personalized features
Welcome to Multibagg AI
Log in to access personalized features
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Invicta Diagnostic Limited, operating under the brand 'PC Diagnostics', is a prominent diagnostic chain concentrated in the Mumbai Metropolitan Region (MMR). The company provides a comprehensive suite of radiology and pathology services through its network of 7 diagnostic centres and one centralized laboratory. Utilizing a 'hub and spoke' model, it delivers integrated diagnostics, ranging from basic tests at spoke centres to advanced imaging like MRI, CT, and PET-CT scans at its flagship and hub locations, positioning itself as a one-stop solution for patients.
Dec 01, 2025
Dec 03, 2025
Dec 08, 2025
SME
Closed
28.12 Cr
28.12 Cr
0 Cr
₹80 - ₹85
1600
The net proceeds from this issue are proposed to be utilized for the following key objectives:
Funding the capital expenditure of ₹21.11 Crores for the purchase of medical equipment to establish five new diagnostic 'hub' centres in key Maharashtra locations, including Kalyan, Vasai-Virar, Malad-Kandivali, and Akola, as part of the company's 'hub and spoke' expansion model.
Allocating a portion of the proceeds for general corporate purposes, which may include meeting working capital requirements, funding growth opportunities, and covering other operational expenses, not to exceed 15% of the gross proceeds.
5.26
9.4
44.28%
42%
36.25%
—
16.38%
30.57%
5.26
Expanding presence in the Mumbai Metropolitan Region (MMR) with a specific focus on the high-growth radiology sector.
Provides a one-stop solution for a wide range of pathology and advanced radiology tests at affordable prices.
Possesses strong technical capabilities with modern IT infrastructure including LIMS and PACS, and advanced diagnostic equipment.
Led by a dedicated management team with significant experience and expertise in the diagnostics industry.
Heavy reliance on a concentrated geographical area, with all diagnostic centers located in the Mumbai Metropolitan Region.
Dependence on third-party suppliers for critical diagnostic equipment and reagents, posing supply chain risks.
High operating costs associated with expensive medical equipment, reagents, and the need for specialized personnel.
Limited operating history as the entity was incorporated in 2021, which may affect long-term performance evaluation.
Significant growth potential in the Indian diagnostic market, which is projected to expand at a double-digit CAGR.
Rising health awareness and a growing focus on preventive healthcare are increasing the demand for regular diagnostic testing.
The expanding medical tourism sector in India creates new opportunities for high-quality diagnostic service providers.
Opportunity to expand into underserved Tier 2 and Tier 3 cities in Maharashtra and beyond, tapping into new markets.
Intense competition from established national chains, hospital-based labs, and new entrants from adjacent healthcare sectors.
Rapid technological advancements in diagnostics may require frequent and costly equipment upgrades to remain competitive.
Potential for reputational damage and legal liability arising from misdiagnosis, errors, or lapses in quality control.
Exposure to regulatory risks from changing laws, rules, and interpretations in the healthcare and taxation domains.
Invicta Diagnostic Limited, operating under the brand 'PC Diagnostics', is a prominent diagnostic chain concentrated in the Mumbai Metropolitan Region (MMR). The company provides a comprehensive suite of radiology and pathology services through its network of 7 diagnostic centres and one centralized laboratory. Utilizing a 'hub and spoke' model, it delivers integrated diagnostics, ranging from basic tests at spoke centres to advanced imaging like MRI, CT, and PET-CT scans at its flagship and hub locations, positioning itself as a one-stop solution for patients.
The Invicta Diagnostic Ltd. IPO is scheduled to open for subscription on Dec 01, 2025 and close on Dec 03, 2025. Investors can apply for shares during this period through eligible platforms.
The price band for the Invicta Diagnostic Ltd. IPO is ₹80 to ₹85. Investors can place bids within this range once the issue opens.
The minimum lot size for the Invicta Diagnostic Ltd. IPO is 1600 shares. The minimum investment amount ₹1,36,000.
The total issue size of the Invicta Diagnostic Ltd. IPO is approximately ₹28.12. Issue size represents the total value of shares offered to the public.
As per the latest available information, the Invicta Diagnostic Ltd. IPO has been subscribed 0.95 times. Subscription levels can change significantly during the offer period.
The Grey Market Premium (GMP) for the Invicta Diagnostic Ltd. IPO is not available as of now. GMP reflects unofficial market sentiment and should not be considered a guarantee of listing performance.
The shares of Invicta Diagnostic Ltd. are expected to list on stock exchanges on Dec 08, 2025, subject to completion of the allotment process and regulatory approvals.
The net proceeds from the Invicta Diagnostic Ltd. IPO are proposed to be used for The net proceeds from this issue are proposed to be utilized for the following key objectives:, Funding the capital expenditure of ₹21.11 Crores for the purchase of medical equipment to establish five new diagnostic 'hub' centres in key Maharashtra locations, including Kalyan, Vasai-Virar, Malad-Kandivali, and Akola, as part of the company's 'hub and spoke' expansion model., Allocating a portion of the proceeds for general corporate purposes, which may include meeting working capital requirements, funding growth opportunities, and covering other operational expenses, not to exceed 15% of the gross proceeds.
Before applying for the Invicta Diagnostic Ltd. IPO, investors generally review the company’s business model, financial performance, valuation, industry outlook, and risk factors mentioned in the offer document.
